Executive Management

Mr. Burns has served as our chief executive officer and as a member of our Board of Directors since March 2002. In December 2021, he was appointed Chairman of the Board. He also previously served as our president from March 2002 to March 2022. Mr. Burns was also a founder and member of the board of directors of DOSE Medical Corporation (acquired by Glaukos), serving as its chairman of the board from October 2009 until June 2019 and its chief executive officer and president from March 2010 until June 2015. Mr. Burns has a proven record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. He has raised nearly $400 million in enterprise capital in private and public offerings and has led and helped build multiple start-up companies. Mr. Burns has more than 25 years of direct ophthalmic management experience, including over 20 years of general management experience across a broad range of ophthalmic medical devices and pharmaceuticals, drug delivery technologies, surgical products and over-the-counter products. Prior to joining our Company, Mr. Burns led Eyetech Pharmaceuticals, Inc. (acquired by OSI Pharmaceuticals, Inc.) as its president and chief operating officer and as a director. From 1990 to 1997, Mr. Burns served as senior vice president and general manager of Chiron Vision Corporation (acquired by Bausch & Lomb, Inc.), and then as vice president, global strategy and general manager, refractive surgery, of Bausch & Lomb from 1998 to 2000. In October 2020, Mr. Burns joined the board of directors of Pulmonx Corporation (Nasdaq: LUNG). He served on the board of directors of Avedro from July 2018 until his resignation on August 6, 2019, prior to its acquisition by Glaukos. Mr. Burns has also served as an entrepreneur in residence at Versant Ventures Management, LLC. Mr. Burns received a B.A. from Yale University.

Mr. Gilliam has served as our president and chief operating officer since April 2022. He previously served as our chief financial officer and senior vice president, corporate development since joining Glaukos in May 2017. Mr. Gilliam has nearly 20 years of experience across capital markets, strategic advisory, finance and banking services with an emphasis on the life sciences industry, including the medical technology, diagnostics and biotechnology sectors. From 2013 to May 2017, he was a managing director in the healthcare investment banking group at JPMorgan, where he led the Glaukos initial public offering for the firm. From 2001 to 2013, Mr. Gilliam held increasingly responsible positions at JPMorgan, with experience spanning mergers and acquisitions, primary and secondary public equity offerings, bank lending, bond offerings and other transactions. His prior experience includes positions at The Beacon Group (which was combined with JPMorgan and Chase Manhattan in 2001) and PricewaterhouseCoopers. Mr. Gilliam has a B.S. in accounting from the Kelly School of Business at Indiana University.

Dr. Navratil has served as our chief development officer since April 2022. He previously served as our senior vice president, research and development since joining Glaukos in October 2020. Dr. Navratil has nearly 20 years of experience in ophthalmic drug and medical device R&D and regulatory affairs spanning new chemical entities, novel medical devices, sustained release drugs and novel routes of administration, Phase 1-4 clinical programs, and regulatory submissions to the U.S. Food & Drug Administration, the European Medicines Agency, and regulatory authorities in Asia Pacific. From 2017 to October 2020, Dr. Navratil served in several leadership positions at the Nicox group, including general manager of Nicox Ophthalmics, Inc. and executive vice president and global head of R&D for Nicox S.A. Prior to joining Nicox, he served as senior vice president of development at Envisia Therapeutics. Prior to Envisia Therapeutics, Dr. Navratil held several director-level positions in drug discovery, clinical research and development, and medical affairs at Parion Sciences and Inspire Pharmaceuticals. He has been issued multiple patents and authored multiple publications on ocular and pulmonary drug delivery and product development. Dr. Navratil was a Morehead Scholar and received his B.S. and Ph.D. in chemistry from the University of North Carolina at Chapel Hill.

Mr. Thurman has served as our senior vice president, chief financial officer since April 2022. He previously served as our vice president, finance from December 2016 to March 2022, and before that as our vice president, global tax and administration when he joined Glaukos in July 2016 through November 2016. Mr. Thurman has been instrumental in building out the company’s finance organization by overseeing significant growth of the finance team, navigating the transition to SOX compliance, instituting the financial infrastructure to serve 16 new international direct sales markets and leading the integration of the company’s new ERP system from a financial perspective. Prior to Glaukos, he held increasingly responsible financial and tax leadership positions over 20 years at Allergan, Inc., Deloitte and Arthur Andersen. Mr. Thurman has a B.S. in Accounting and Master of Accountancy in Tax from Brigham Young University and received a CPA license (inactive) from the state of California.

Michele M. Allegretto has served as our senior vice president, human resources since April 2019. She was previously our vice president, human resources, a position she had held since joining Glaukos in May 2015. From October 2005 to May 2015, Ms. Allegretto served as director global business human resources with Abbott Medical Optics, a global ophthalmic medical device division of Abbott Laboratories. From January 2002 to October 2005, Ms. Allegretto was director of human resources for The Wet Seal, Inc., a publicly traded national women’s retail chain. From April 1995 to December 2001, Ms. Allegretto served in several different leadership positions across three divisions of The Walt Disney Company, including the director recruitment for Walt Disney Studios. Ms. Allegretto holds a B.A. from San Diego State University and a master’s degree from California State University, Long Beach.

Diane W. Biagianti has served as our senior vice president and general counsel since June 2020. From May 2011 to May 2020, Ms. Biagianti was vice president, chief responsibility officer at Edwards Lifesciences, LLC, where she was responsible for that company’s global ethics and compliance programs and corporate sustainability. From April 2009 to May 2011, she served as divisional vice president, legal, for Abbott Medical Optics, where she was responsible for all legal matters relating to this division of Abbott Laboratories. From May 2002 to April 2009, she served in a number of positions at Advanced Medical Optics, Inc. (acquired by Abbott Laboratories), including senior vice president, general counsel and assistant secretary, where she headed the legal department with responsibility for compliance, litigation, regulatory, corporate governance, intellectual property and general commercial matters. From 1997 through 2002, Ms. Biagianti was vice president, assistant general counsel at Experian Information Solutions and from 1991 to 1997, she was an associate with the law firm of O’Melveny & Meyers, LLP. Ms. Biagianti is an active member of the California State Bar and a certified public accountant, previously licensed to practice in Arizona. She received a J.D. from Cornell Law School and a B.S. from the University of Arizona.

Mr. Calcaterra has served as our executive vice president, global commercial operations since April 2022. He previously served as our chief operating officer from February 2017 to March 2022, and as our chief commercial officer from April 2008 to January 2017. Mr. Calcaterra has more than 30 years of experience in the ophthalmic medical technology industry. Prior to joining our Company, Mr. Calcaterra was senior vice president at Advanced Medical Optics, Inc. (acquired by Abbott Laboratories), and was responsible for its cataract business. Prior to that position, Mr. Calcaterra held increasingly responsible vice president positions in a variety of sales and marketing roles at Advanced Medical Optics, Inc., as well as its predecessor surgical division business at Allergan, Inc. Mr. Calcaterra has a B.S. from Miami University and an M.B.A. from Xavier University, and he was previously a board member of WaveTec Vision Systems, Inc. (acquired by Novartis).

David S. Haffner has served as our executive vice president, new technologies since February 2017. He was previously our vice president, product development, a position he had held since joining Glaukos in February 2001. Immediately prior to joining our company, Mr. Haffner consulted to the medical industry in the areas of medical device and pharmaceutical product development, with emphasis on mechanical systems for pharmaceutical drug delivery. Prior to this, he spent over 10 years at Allergan, Inc. leading teams and departments in several divisions, including surgical products, pharmaceuticals, and worldwide operations. Mr. Haffner has directed several multi-million dollar programs in both research and development and operations involving development and commercialization of ophthalmic products and technologies targeted at cataract, glaucoma, dry eye and nasal disease groups. The scope of his work has spanned a broad diversity of technical disciplines including operations management, process development, site construction, validation, injection molding, automated assembly, packaging, product design, engineering analysis, and industrial design. Mr. Haffner holds a B.S. from California State University, Long Beach.

Dr. Katz has served as our Chief Medical Officer since February 2017. He is currently employed by our company on a part-time basis while maintaining his Philadelphia-based ophthalmology practice and involvement in clinical research and medical education. Dr. Katz completed his glaucoma fellowship at Wills Eye Hospital in Philadelphia in 1985 and has been affiliated with the hospital since that time, currently serving as its director of glaucoma service. Since 1997, he has also served as a professor of ophthalmology at Jefferson Medical College at Thomas Jefferson University. He is a former member of the board and past treasurer of the American Glaucoma Society, a diplomate and associate examiner for the American Board of Ophthalmology and a fellow, member-at-large and past president of the Philadelphia Metro chapter of the American College of Surgeons. He has published more than 200 articles in ophthalmic journals and served as an investigator in landmark glaucoma trials, including the Advanced Glaucoma Intervention Study (AGIS) and Collaborative Initial Glaucoma Treatment Study (CIGTS). Dr. Katz completed his residency at Yale University and internship at the University of Virginia after earning his M.D. from Yale University Medical School. He holds a B.A. (summa cum laude) from Case Western Reserve University.

Jane E. Rady has served as our senior vice president, corporate strategy and business development since April 2018. From 2017 to April 2018, she was vice president, business development for Johnson & Johnson Surgical Vision, following the 2017 acquisition by Johnson & Johnson of Abbott Medical Optics, a division of Abbott Laboratories. From 2009 to 2017, she was divisional vice president, business development for Abbott Medical Optics. From 2002 to 2009, she held several executive leadership positions at Advanced Medical Optics, Inc. (AMO), which was acquired by Abbott Laboratories in 2009. While at AMO, Ms. Rady headed various functions, including business development, strategic planning, research and development, clinical development, regulatory affairs and government affairs. Her prior experiences includes positions at Monsanto Corporation, G.D. Searle and Abbott Laboratories. Ms. Rady holds a B.S. in biology and a M.S. in molecular biology/microbiology from the University of Illinois and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.

Dr. Szekely has served as our vice president, research and development, combination pharmaceutical products since September 2018. She previously served as our vice president, translational sciences since joining Glaukos in 2015. Dr. Szekely has over 20 years of experience in pharmaceutical drug development and life sciences industry product development. Between 2008 and 2015, she held positions of increasing responsibilities at Allergan, most recent being vice president of translational sciences within the nonclinical safety sciences organization that included oversight of the nonclinical pharmacokinetics and drug disposition, clinical pharmacology, formulation laboratories, and scientific operations. Prior to that, she held several leadership positions at Assay Designs/Enzo Life Sciences from 2007 to 2008, Pfizer’s research and development laboratories from 2001 to 2007, and 3M from 1997 to 2001. Dr. Szekely completed her doctorate in physical chemistry at the Kossuth University in Hungary and Ph.D. in chemistry at Michigan State University.

Matt Young has served as our senior vice president, global operations since October 2022. He previously held positions of vice president and senior director of global operations since joining Glaukos in 2016. Mr. Young has 25 years of experience in the medical technology industry spanning medical devices and drug-device combination products. From 2011 to 2016, he was director of manufacturing operations, engineering and new product introduction with Edwards Lifesciences. Between 2006 to 2011, Mr. Young held several leadership positions in operations and engineering at Abbott Vascular. From 1996 to 2006, he held positions of increasing responsibility at Kimberly-Clark Healthcare, spanning multiple functions including research and development, engineering and operations. Mr. Young holds a B.S. in material science and engineering from the University of Florida and an M.B.A. from the University of Arizona.